Tag: Antibody therapy

The global monoclonal antibody therapeutics market was valued at over $233 billion in 2023 and is projected to grow significantly [1.4.7]. For clinicians and patients wondering, *How can you recognize a monoclonal antibody drug?* The secret is systematically encoded in its generic name.

With an estimated prevalence of 1 in 1,200 individuals, Primary Immunodeficiencies (PI) affect a significant population [1.3.5]. For many, a key question is: **what is the immune globulin injection used for?** This therapy is a lifeline, providing essential antibodies to fight infection and regulate the immune system [1.6.5, 1.11.2].

Founded in 2008, argenx is a global immunology company with a primary focus on improving the lives of people living with severe autoimmune diseases by translating immunology breakthroughs into a portfolio of innovative antibody-based medicines. The key question, "What does argenx do?", is answered through its strategic focus on targeting the underlying biology of these conditions with its proprietary technology platforms.